In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

Multiple new deals and developments and new base editor data from Intellia Therapeutics

This week’s update looks at a Phase 1 clinical trial for a new meganuclease-edited CAR T-cell therapy for Non-Hodgkin lymphoma (NHL).